<DOC>
	<DOCNO>NCT01126216</DOCNO>
	<brief_summary>Reduced RT Pac/Cis vs. standard RCT 5-FU/Cis</brief_summary>
	<brief_title>Reduced Radiotherapy With Pac/Cis v Standard Radiotherapy With 5-FU/Cis Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>Standard treatment patient advance , unresectable head neck cancer platin-based simultaneous radiochemotherapy ( RCT ) ( Pignon JP et al. , Lancet 2000 ; 355:949-955 ) . However , irradiation dose still debatable regard local tumor control late toxicity . Moreover , still unclear combination different drug might effective . In recent year , new drug introduce field head neck cancer . The Taxanes , namely Docetaxel Paclitaxel , investigate several phase I/II-studies , show promising result concern locoregional control rate survival data . The RTOG 97-03 trial ( Garden et al. , J Clin Oncol 2004 ; 22:2856-64 ) compare RCT either Cisplatin/5-FU Cisplatin/Paclitaxel . In phase II-study improvement local tumor control disease free survival 15-20 % favour Cisplatin/Paclitaxel treatment arm see . Therefore , phase III-trial compare standard RCT ( 70.6 Gy ) Cisplatin/5-FU RCT Cisplatin/Paclitaxel reduce irradiation dose ( 63.6 Gy ) . Primary endpoint proof superiority experimental Cisplatin/Paclitaxel treatment arm concern disease-free-survival . Secondary endpoint locoregional tumor control , overall survival quality life .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven , locally advanced stage IIIIV AB ( UICC 2002 ) primary squamous cell carcinoma oral cavity , oropharynx , hypopharynx , supraglottic larynx Age ≥ 18 Written inform consent participation clinical trial Inadequate hepatic function : Bilirubin &gt; 2,0 mg/dl , SGOT , SGPT , AP , GammaGT &gt; 3 x ULN Inadequate bone marrow function : leukocytes &lt; 3,5 x 10^9/l , platelet &lt; 100 x 10^9/l neutrophil &lt; 1,5 x 10^9/l Serum creatinine &gt; 1,5 mg/dl , creatinine clearance &lt; 60ml/min Uncontrolled severe somatic psychological disease : e.g . unstable angina pectoris ; myocardial infarction last 6 month ; significant cardial rhythm disorder ; apoplexy ; high grade stenosis carotis ; neurological psychiatric disorder include convulsive disorder ; dementia ; psychosis ; active uncontrolled infection sepsis ; liver cirrhosis ; Child stage B , C ; severe liver function disorder ; marginal change blood count ; severe kidney damage ; HIVinfection Acute infection Fertile woman without adequate contraception 6 month therapy ( method contraception high effective describe Note guidance nonclinical safety study conduct human clinical trial pharmaceutical ( CPMP/ICH/286/95 mod ) discuss investigator ) Pregnant breast feed woman Men , willing use adequate contraception 6 month therapy , discuss investigator ECOGStatus &gt; 1 Reduced hearing function ( especially high frequency ) Exsiccosis Neuropathy , cause cisplatin Concurrent malignancy , exception adequately treat basal cell carcinoma skin situ carcinoma cervix Prior radiotherapy neck chemotherapy Distant metastasis Recurrent carcinoma head neck region Prior neckdissection surgical intervention exceed exploratory excision Known intolerance 5Fluorouracil Known deficit Dihydropyrimidine dehydrogenase ( DPD ) Simultaneous therapy Brivudin inhibitor DPD Known intolerance Cisplatin substances contain platin Known intolerance Paclitaxel one include substance , especially Poly ( oxyethylene ) Rhizinusöl/Macrogolglycerol ricinoleate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Radiochemotherapy</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>5-FU</keyword>
</DOC>